Differential drug therapy of the hyperlipoproteinaemias. The efficacy of lipid lowering drugs alone and in combination.
In a trial of lipid lowering drugs a 6 week course of treatment gives reasonably reproducible post-treatment values. Comparison of serum cholesterol and triglyceride levels after treatment should be preferred to percentage reductions, in both individual patients and groups of patients. Therapy with clofibrate combined with Bufor gives lower post-treatment values than does either drug alone. Cholestyramine drugs like Cuemid and Questran give post-treatment cholesterol values which cannot be predicted from the result of clofibrate treatment alone.
D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000008:administration & dosage / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009531:Niceritrol / Q000008:administration & dosage / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol; D009531:Niceritrol; D002994:Clofibrate